Wenting He

Wenting He


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YCYue Chen
Yue Chen
DZDachuan Zhang
Dachuan Zhang
HYHaonan Yang
Haonan Yang
JWJun Wu
Jun Wu
WHWenting He
Wenting He
Disulfidptosis, a recently identified cell death mechanism, plays a pivotal role in the development, progression, and treatment of digestive tract tumors, including gastric cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, and neuroendocrine tumors, which have high global incidence and mortality rates. Analyzing the expression of disulfidptosis-related gene expression within the tumor microenvironment enhances our understanding of tumor biology and facilitates novel diagnostic and therapeutic strategies. Research on immune infiltration and checkpoints can identify therapeutic targets linked to disulfidptosis, thereby improving immunotherapy efficacy. Targeting genes such as SLC7A11, which are essential for maintaining glutathione levels and regulating oxidative stress, may overcome chemoresistance and enhance existing treatments. Disulfidptosis could complement current therapies as it induces cytoskeletal collapse and selective tumor cell death, especially in chemoresistant cancers. Additionally, genes like SLC7A11, RPN1, and NCKAP1 in gastric cancer correlate with poor prognosis, highlighting their potential as prognostic biomarkers. Personalized medicine approaches utilizing disulfidptosis-related biomarkers could identify patients who would benefit from therapies targeting oxidative stress regulation, leading to more precise treatments and improved outcomes. This review summarizes disulfidptosis mechanisms, advancements in digestive cancers, and the potential of related genes for prognosis, immune response evaluation, and targeted therapies, providing novel perspectives for diagnosis and personalized treatment.

2 January 2026 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YCYue Chen
Yue Chen
JWJun Wu
Jun Wu
DZDanxia Zhu
Danxia Zhu
LJLu Jiang
Lu Jiang
JWJian Wang
Jian Wang
WHWenting He
Wenting He
Cholangiocarcinoma (CCA) is an aggressive malignancy with poor prognosis and a limited number of treatments is available. Disulfidptosis, a newly identified form of cell death triggered by disulfide bond accumulation during glucose deprivation, may influence cancer progression but its role in CCA is poorly understood. The present study investigated disulfidptosis‑related genes (DRGs) and their impact on CCA prognosis and immune modulation. Differential expression analysis of 100 DRGs using RNA sequencing data from The Cancer Genome Atlas and EMBL‑EBI identified 74 dysregulated genes in CCA. Unsupervised clustering stratified patients with CCA into two distinct subtypes (Subs): i) SubA; and ii) SubB. A four‑gene prognostic signature was developed using least absolute shrinkage and selection operator regression and validated via Kaplan‑Meier survival analysis and receiver operating characteristic curves. Immune infiltration and tumor microenvironment were evaluated using Cell‑type Identification by Estimating Relative Subsets of RNA Transcripts, Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data and single‑sample Gene Set Enrichment Analysis. Functional assays, including small interfering RNA knockdown of CD109 and EFNB2 in CCA cell lines were used to investigate proliferation, migration, invasion and F‑actin staining. Results showed SubB, associated with higher disulfidptosis activity, had worse prognosis, increased immune cell infiltration and elevated immune checkpoint gene expression. The four‑gene signature effectively stratified patients into risk groups. Knockdown of CD109 and EFNB2 significantly suppressed CCA cell proliferation, migration and invasion while it promoted disulfidptosis under glucose deprivation. The present study established an association between DRGs and CCA prognosis/immune dynamics, provided a robust four‑gene prognostic signature, and identified CD109 and EFNB2 as potential therapeutic targets, positioning disulfidptosis as a promising focus for precision medicine in CCA.

3 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YMYu Meng
Yu Meng
FWFang Wei
Fang Wei
YZYe Zhang
Ye Zhang
WHWenting He
Wenting He
HYHaijiao Yan
Haijiao Yan
JWJun Wu
Jun Wu
Cholangiocarcinoma (CCA) is an aggressive tumor that originates from the epithelial cells of the bile duct and has the ability to metastasize to the liver or lymph nodes at an early stage. CCA metastasis represents a complex, multi-stage cascade process. Among these stages, the acquisition of invasiveness by CCA cells is a critical prerequisite for metastatic progression. Elucidating the molecular mechanisms driving CCA cell invasiveness is critical for advancing our knowledge in this field. Emerging evidence highlights the critical role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). These molecules orchestrate key processes such as the epithelial–mesenchymal transition (EMT), as well as the migration and invasion of CCA cells. Collectively, these processes ultimately drive tumor progression. This review comprehensively synthesizes the expression, biogenesis, interactions, signaling pathways, and functional mechanisms of ncRNAs in the invasiveness of CCA. Furthermore, the review discusses potential clinical applications of ncRNAs, including their roles as diagnostic tools, therapeutic targets, and prognostic markers. These investigations offer novel insights and evidence for identifying early metastasis in CCA, developing specific therapeutic strategies, and enhancing drug resistance.